DOW JONES25,409.36-357.28 -1.39%
S&P 5002,954.22-24.54 -0.82%
NASDAQ8,567.37+0.89 0.01%

Credit Suisse Maintains Neutral on Biogen, Raises Price Target to $330

Credit Suisse maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $300 to $330.

Benzinga · 02/06/2020 13:53

Credit Suisse maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $300 to $330.